Alterity Therapeutics Ltd (ATHE) - Total Assets
Based on the latest financial reports, Alterity Therapeutics Ltd (ATHE) holds total assets worth $56.86 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Alterity Therapeutics Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Alterity Therapeutics Ltd - Total Assets Trend (1998–2025)
This chart illustrates how Alterity Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. Explore ATHE long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Alterity Therapeutics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Alterity Therapeutics Ltd's total assets of $56.86 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.0% |
| Accounts Receivable | $3.94 Million | 8.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1998–2025)
This chart illustrates how Alterity Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Alterity Therapeutics Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alterity Therapeutics Ltd's current assets represent 99.7% of total assets in 2025, an increase from 0.0% in 1998.
- Cash Position: Cash and equivalents constituted 72.0% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
- Asset Diversification: The largest asset category is accounts receivable at 8.6% of total assets.
Alterity Therapeutics Ltd Competitors by Total Assets
Key competitors of Alterity Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Alterity Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.98 | 3.84 | 12.28 |
| Quick Ratio | 21.98 | 3.84 | 12.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $54.18 Million | $7.71 Million | $34.33 Million |
Alterity Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Alterity Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.83 |
| Latest Market Cap to Assets Ratio | 1.54 |
| Asset Growth Rate (YoY) | 139.4% |
| Total Assets | $46.03 Million |
| Market Capitalization | $70.69 Million USD |
Valuation Analysis
Above Book Valuation: The market values Alterity Therapeutics Ltd's assets above their book value (1.54x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Alterity Therapeutics Ltd's assets grew by 139.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alterity Therapeutics Ltd (1998–2025)
The table below shows the annual total assets of Alterity Therapeutics Ltd from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $46.03 Million | +139.42% |
| 2024-06-30 | $19.22 Million | -29.63% |
| 2023-06-30 | $27.32 Million | -33.96% |
| 2022-06-30 | $41.36 Million | +23.16% |
| 2021-06-30 | $33.59 Million | +152.43% |
| 2020-06-30 | $13.30 Million | -33.17% |
| 2019-06-30 | $19.91 Million | +6.32% |
| 2018-06-30 | $18.73 Million | -25.93% |
| 2017-06-30 | $25.28 Million | -25.04% |
| 2016-06-30 | $33.73 Million | -19.38% |
| 2015-06-30 | $41.83 Million | +0.46% |
| 2014-06-30 | $41.64 Million | +143.89% |
| 2013-06-30 | $17.07 Million | +132.55% |
| 2012-06-30 | $7.34 Million | -18.52% |
| 2011-06-30 | $9.01 Million | +32.49% |
| 2010-06-30 | $6.80 Million | +47.95% |
| 2009-06-30 | $4.60 Million | -60.79% |
| 2008-06-30 | $11.72 Million | +51.85% |
| 2007-06-30 | $7.72 Million | -25.96% |
| 2006-06-30 | $10.43 Million | -53.03% |
| 2005-06-30 | $22.20 Million | -46.07% |
| 2004-06-30 | $41.16 Million | +151.90% |
| 2003-06-30 | $16.34 Million | -7.10% |
| 2002-06-30 | $17.59 Million | -21.07% |
| 2001-06-30 | $22.29 Million | +6.76% |
| 2000-06-30 | $20.88 Million | +1036.48% |
| 1999-06-30 | $1.84 Million | +821.77% |
| 1998-06-30 | $199.28K | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more